Lexology August 22, 2022
Epstein Becker Green

On August 16, 2022, President Biden signed into federal law the Inflation Reduction Act (IRA), which, among other priorities for the Biden administration, addresses prescription drug costs and drug prices in the Medicare program.[1]

Specifically, the provisions provide new federal authority for the federal government to negotiate pricing for certain Medicare Part D and Medicare Part B drugs. Other notable provisions create new caps on out-of-pocket spending for drugs in Part D, including for insulin and adult vaccines; provide penalties for prices of Part B or D drugs that increase faster than inflation; increase Part B reimbursement rates for biosimilars; and extend the moratorium on the U.S. Department of Health & Human Services (HHS) Office of Inspector General’s rebate rule...

Today's Sponsors

Zelis
HealthITq
Premier

Today's Sponsors

Upfront Healthcare
pCare

Today's Sponsor

Curation Health

 
Topics: Congress / White House, Govt Agencies, Pharma, Pharma / Biotech, Regulations, Supply Chain, Technology
Biden’s New Executive Order Could Usher in an Era of Fair and Equitable Drug Pricing
Mark Cuban in talks with hospitals to solve drug shortages
Why should pharma invest in digital products for those living with rare diseases?
FDA approves most expensive drug on market
What Has COVID Ever Done For Us? Here 9 Examples